

## Now Enrolling: The Canopy ADHD Study

*A clinical study using an investigational drug for core symptoms of Attention-deficit/Hyperactivity Disorder*

We are currently looking for participants ages 6-17 with Attention-deficit/Hyperactivity Disorder (ADHD) for an open-label clinical trial involving an investigational drug. The purpose of this study is to evaluate the long-term safety and tolerability of the study drug, Centanafadine, for the treatment of children and adolescents experiencing ADHD symptoms, such as hyperactivity, inattentiveness and impulsivity.



### STUDY SNAPSHOT:

- Study Duration: 52 weeks (with option to continue up to 136 weeks)
- Total Study Visits: 17 visits (all in person) + 1 phone call for follow-up
- If continuing past the minimum 52 weeks, there will be an in-office visit that takes place every 12-weeks

### ELIGIBILITY REQUIREMENTS INCLUDE:

- Individuals ages 6-17
- Cannot have an ASD diagnosis
- Must have an ADHD diagnosis
- Must weigh at least 28.7 lbs

Learn more at  
[autismcenter.org/research](https://autismcenter.org/research)

To learn more or enroll, contact  
SARRC's research team at:



480.701.3681



[ZMerritt@autismcenter.org](mailto:ZMerritt@autismcenter.org)